AI researcher Richard Socher is looking to raise funds for his new startup at a roughly $4B valuation before the new capital is added. Investors involved in discussions include GV, formerly known as Google Ventures, and Greycroft. The company is exploring approaches aimed at so-called superintelligence, which are AI systems that could outperform humans.

Reflection AI, an NVIDIA backed open-source AI startup, is in talks with investors at a valuation above $20 billion. A surge from its $8 billion valuation in October 2025, when it raised $2 billion. The move signals intense investor appetite for frontier AI models and autonomous coding agents, positioning the startup as a key open-source alternative to closed labs.

Valar Atomics has closed a new funding round at a valuation of $2 billion. The startup brought in a total of $450 million in the deal, including $110 million in debt and $340 million in equity. Valar aims to build clusters of small nuclear reactors to power sites that consume large amounts of energy, like artificial intelligence data centers.

Reflection AI is in advanced discussions to raise $2.5 billion at a $25 billion pre-money valuation, with Nvidia and JPMorgan Chase among the key backers. This marks a dramatic surge from the $8 billion valuation the company commanded just five months prior, underscoring the intense investor appetite for AI companies building at the frontier.

POSH, the network feeding New York’s social pulse secures a $22 million Series A led by Goodwater with FirstMark, Companyon, and Epic joining Day One Ventures. For Halloween, POSH went #2 on App Store, tracking $95+ million in ticket flows and a 1400% Year-on-Year spike in algorithmic matching tightens its grip on who meets where and when.

After three years in stealth, World.org - the digital ID network co-founded by OpenAI’s Sam Altman and Alex Blania - went live July 2023, offering every user a cryptographically verified identity fused to a Visa wallet, a seamless credential for living, paying, and biometric recognition across the global ecosystem.

Artisan, the YC-backed engine behind viral campaigns and AI “employees” called Artisans, secures a $25 million Series A led by Glade Brook Capital, the $2 billion growth fund with stakes in xAI, Perplexity, Stripe, Revolut, SpaceX, Airbnb, and Uber-fuel for a workforce of tireless synthetic minds built to outnumber and outlast the human kind.

AI has not ended creativity — it ended mediocrity. In a world where algorithms generate quality output infinitely, the “average” creator ceases to matter. What emerges isn’t replacement but stratification: those who direct machines ascend; those who imitate them disappear.

Superpower, built as a gateway to self-command. Unveils the world’s first health super-app. Starting with sweeping biomarker scans that map the body like code, it promises proactive, personalized care while drawing every vital signal into a single, luminous network-a quiet system built to know you before you know yourself.

Richard Socher, Founder & CEO of You.com & General Partner at AIX Ventures is launching a new AI lab focused on automating AI research, taking a different approach from model-scaling labs like OpenAI and Anthropic. The lab has seven co-founders, including former OpenAI researcher and Cresta co-founder Tim Shi.

Walkway is the first AI-powered growth platform for tour and activity providers, helping them optimize pricing, track competitors, and increase revenue. Built by a founding team from Airbnb, Kayak, Regiondo, and Rezdy, it’s creating the industry’s most comprehensive pricing and demand dataset to become the go-to revenue intelligence platform for experience operators.

AnyRoad unveils validated Lifetime Loyalty platform, driving a 150% increase in member spending with partners including Heaven Hill, Nearest Green, Lux Row, Castle & Key, and Catoctin Creek, with EU expansion in the works.

Mindstate Design Labs, a Y-Combinator backed startup, is combining machine learning with the conscious experience to map how psychedelic compounds shape human experience. The company has cleared a major hurdle with FDA approval to initiate Phase 1 clinical trial in the Netherlands.